The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
ACC 2023 Coverage: Topics in Cardio-oncology
Coverage from the American College of Cardiology Scientific Session Together With World Congress of Cardiology, held March 4-6, 2023, in New Orleans, Louisiana.
OneOncology’s Clinical Pathways Covers Best Practices for 90% of Patients, Says Ted Arrowsmith, MD, MPH
State Legislatures Lead the Way on Policy Reform to Protect Personalized Medicine
Building More Diverse Clinical Trials in Oncology: Strategies for Providers, Payers, and Community Stakeholders
Spotlights From Our Cochairs: Joseph Alvarnas, MD, Explains Barriers to Clinical Trial Diversity and Payer Participation
COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.
FDA Accepts Futibatinib for Priority Review for FGFR2 Rearrangements and Fusions in Cholangiocarcinoma
Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma.
Further Analysis Needed to Incorporate Liquid Biopsy in the Community Setting
This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.
Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study
A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.
Improvement Needed for Liquid Biopsy to Have Clinical Utility in Lung Cancer
This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.
More Info Needed to Establish Utility of MRD, SFLC Levels as Biomarkers in MM
This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.
ctDNA Detection in RCC Requires More Sensitive Detection Methods
Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.
Liquid Biopsy May Have Prognostic, Theranostic Benefits in PDAC
Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.
Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer
Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Point-of-Care Testing Has Potential to Expand the Reach of NGS for CRC
This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).
MRD Continues to Reliably Predict Disease Progression in CRC
In this poster presented at the 2022 ASCO Gastrointestinal Cancers Symposium, minimal residual disease (MRD) status as detected by postsurgery plasma cell-free DNA continued its strong track record of being a reliable predictor of disease progression in colorectal cancer (CRC).
Understanding Real-World Trends in MRD Testing as Part of MM Management
An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.
MRD Kinetics Identify High-risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab
An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.
Review Explores Adoption of New MRD Monitoring Method
A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.
Targeted Cancer Therapies Showing Promise in Treating Parenchymal Brain Metastases
Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.
MRD Indicates Relapse for Patients With Classical HL After ASCT
Minimal residual disease (MRD) can predict which patients with classical Hodgkin lymphoma (HL) will relapse after autologous stem cell transplantation (ASCT).
Ibrutinib/Venetoclax Bests Chlorambucil/Obinutuzumab for Treating CLL
Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.
Top 5 Most-Read Articles in Precision Oncology for 2021
Epigenetics has a role in choosing the right medicine in lung cancer, artificial intelligence can predict outcomes in a highly aggressive cancer, and more.
Precision Medicine Can Close Oncology Gaps—and Lead to “Doing Less”
Physicians said it is in payers’ interest to use artificial intelligence to address social determinants of health, to cover tests, and to gather data. Doing so could let them stratify who needs certain screenings and diagnostic procedures and who doesn’t, which could lead to less consumption of health care.
Daratumumab-Led Quad Therapy Aids MRD Surveillance in MM
Final results from the MASTER trial presented at this year’s 63rd Annual American Society of Hematology Annual Meeting and Exposition bear out the benefits of quadruplet therapy and using minimal residual disease (MRD) status among patients with newly diagnosed multiple myeloma (MM).
Spotlighting Key Therapies in the Oncology Pipeline for the First Half of 2022
From Challenges Spring Opportunities for Progress in Daratumumab-Based Clinical Pathways
An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.
Real-world Study Shows Heterogenous Genomic Landscape of Metastatic LUAD
The study demonstrated the heterogeneity of actionable alterations, PD-L1 expression, and mutational burden among the samples of metastatic lung adenocarcinomas (LUAD).
Tracing the Origins of Minimal Residual Disease
Although advancements in cancer have been many, disease relapse is still a hurdle for many types of tumors and malignancies, and there is an urgent need to overcome tumor resistance.
Exploring the Use of Liquid Biopsy–Based Biosensors for MRD Assessment in NSCLC
In a recent study, researchers detailed the use of various biosensors for minimal residual disease (MRD) detection in non–small cell lung cancer (NSCLC).
2 Clarke Drive Cranbury, NJ 08512